KRTL Holding Group Inc. (OTC: KRTL) (“KRTL” or the “Company”) today provided shareholders with an update on work completed and continuing at the Holding-company level, together with a high-level overview of progress across its three wholly owned subsidiaries: KRTL Biotech Inc., KRTL MedHealth Corp. and KRTL International Corp.
This is the first in a planned series designed to explain the foundation KRTL Holding Group has been working to establish, how the subsidiaries operate independently and together, and what each business has been building before more detailed subsidiary updates are released.
KRTL Holding Group management stated: “A significant part of our work has been cleaning up legacy issues and establishing a corporate and shareholder-record baseline that we can support and build from. At the same time, our subsidiaries have continued developing their own business platforms. This series is intended to connect those efforts and give shareholders a clearer picture of where KRTL stands today.”
KRTL Holding Group — Corporate Cleanup, Baseline and 15c2-11 DiligenceAt the Holding-company level, KRTL has spent significant time addressing legacy corporate and shareholder-record issues. In January 2026, the Company announced that the Third Judicial District Court of Salt Lake County, Utah, had issued a supplemental order authorizing the cancellation of an additional 7,335,311 shares of common stock deemed unverified or non-responsive through KRTL’s court-supervised shareholder-record remediation process. KRTL also disclosed that the Court reaffirmed the Company’s updated shareholder ledger and PCAOB-audited financials as the corporate and financial baseline for public reporting and regulatory disclosure.
Management views court-supervised remediation as an important step in establishing a clearer, more supportable foundation for diligence and future corporate activity. KRTL is continuing its Rule 15c2-11-related work with market makers and other broker-dealers, including organizing issuer information and responding to diligence requests as the process progresses. The Company is not representing that the process has been completed or that any quotation, timing or outcome is assured.
How the KRTL Companies Work TogetherKRTL’s three operating subsidiaries have distinct mandates but can support one another when an opportunity spans more than one area of expertise. Biotech leads life-sciences, pharmaceutical and regulatory development; MedHealth focuses on healthcare operations and MSO services; and International supports cross-border, federal-facing and strategic project development. KRTL Holding Group provides the governance, capital planning, corporate development and coordination connecting the businesses.
KRTL Holding Group Operating Structure
KRTL Biotech Inc. — Life Sciences & Biotechnology
KRTL Biotech has continued assembling the regulatory, technical and commercial components of KRTL’s life-sciences platform, including pharmaceutical and API development, botanical and extract opportunities, research, regulatory planning, partner qualification and commercialization.
A central part of that work involves Rayel and Periko, which remain separate but equal platform assets. Company records include a TTB formula approval record for Rayel Decocainized Natural Coca Extract, providing an existing regulatory foundation for its applicable beverage-facing use. Management is now focused on advancing the commercial arrangements and qualified partner relationships needed to move applicable opportunities toward commercialization. The upcoming KRTL Biotech release will address these programs in greater detail.
KRTL International Corp. — International, Federal & Strategic DevelopmentKRTL International has continued developing the Company’s international, federal-facing and strategic project-development capabilities and is the parent company of KRTL BlueSpot Inc. and KRTL Xylem Inc.
Through KRTL BlueSpot, the Company has established a strategic relationship involving California mining claims and advanced the opportunity into an active diligence and validation phase. Current work includes review of historical, claim, geological and technical information to evaluate the basis for additional exploration and development. This includes the Acton-Area Historic Mineral Validation Project, which will be addressed further in the International update and a later project-specific release.
KRTL MedHealth Corp. — Healthcare Operations & MSO DevelopmentKRTL MedHealth is developing the Company’s healthcare operations and management-services-organization (“MSO”) platform, with a focus on administrative and operational infrastructure supporting physicians, medical practices and provider organizations.
MedHealth is also developing a Medical Group Hub through which participating providers can join and operate within a standardized infrastructure and operating framework. Management intends for the Hub to establish a working proof of concept that can be measured, refined and used as a model that additional providers can follow. The dedicated MedHealth update will explain the MSO model and Medical Group Hub in greater depth.
Building Federal-Market InfrastructureKRTL Biotech, KRTL MedHealth and KRTL International have each established active SAM.gov registrations, giving the individual legal entities federal identities and infrastructure through which they can evaluate qualifying contracting, subcontracting, teaming, research, assistance or other government-facing opportunities aligned with their capabilities.
SAM.gov registration does not constitute a federal contract, award, funding commitment, government endorsement, regulatory approval or guarantee of future revenue. The individual subsidiary releases will provide the applicable registration details and explain how management expects each company to use that infrastructure within its own strategy.
What Comes NextThe next shareholder update will focus on KRTL Biotech Inc., followed by dedicated updates on KRTL International Corp and KRTL MedHealth Corp. A subsequent release will provide a focused update on the Acton-Area Historic Mineral Validation Project. Together, the series is intended to show shareholders what Holding has accomplished, what has been built within the subsidiaries and what milestones management is working toward next.
About KRTL Holding Group Inc.KRTL Holding Group Inc. (OTC: KRTL) provides strategic oversight, corporate development, capital planning and coordination across its wholly owned subsidiaries KRTL Biotech Inc., KRTL MedHealth Corp. and KRTL International Corp.
KRTL Holding Group Inc.
OTC: KRTL
www.krtlholding.com
info@krtlholding.com
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding Rule 15c2-11-related activities, subsidiary development, pharmaceutical and biotechnology initiatives, Rayel and Periko, healthcare and MSO activities, Medical Group Hub development, federal-market opportunities, international and cross-border activities, strategic partnerships, commercialization and the Acton-Area Historic Mineral Validation Project. Forward-looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. There can be no assurance that contemplated quotation-related outcomes, contracts, regulatory approvals, partnerships, financing, development programs or commercialization activities will be obtained or completed.
SAM.gov registration, a UEI, CAGE/NCAGE assignment or other government identifier does not constitute a government contract, award, funding commitment, endorsement, product approval or authorization to conduct an otherwise regulated activity. Neither KRTL Holding Group nor its subsidiaries represents that any pharmaceutical, controlled-substance, healthcare, mineral-development or other regulated activity discussed herein has received authorization or achieved commercial readiness unless specifically stated by the Company.